immunosuppressant
- Generic Name
- immunosuppressant
CAR-T Therapy Shows Promise in UK Trial for Lupus Treatment
• A new CAR-T therapy is being trialed in the UK as a potential cure for lupus, an autoimmune condition affecting approximately 69,000 people in the UK.
• The trial, led by Professor Ben Parker at Manchester Royal Infirmary, aims to 'correct' the immune system using a method previously applied in blood cancer treatment.
• Current lupus treatments involve lifelong immunosuppressants with varying effectiveness, highlighting the need for more effective and potentially curative therapies.
• Early diagnosis and treatment are crucial for managing lupus, as prompt intervention can reduce the risk of long-term damage to affected organs.
CAR T-cell Therapy Shows Promise in Treating Severe Lupus in UK Trial
• Three patients in the UK have received CAR T-cell therapy for severe lupus, a potentially life-threatening autoimmune disease.
• Early results from a German study showed that patients who underwent CAR T-cell therapy are now in remission and do not require lupus medication.
• The NHS trial, led by UCLH and UCL, modifies cells to enable the immune system to recognize and attack problem cells, offering a possible cure.
• Researchers are optimistic that this one-time treatment could revolutionize lupus care, potentially eliminating the need for lifelong medication.
CAR T-Cell Therapy Shows Promise in Treating Severe Lupus in UK Trial
• Three patients in the UK have received CAR T-cell therapy for severe lupus, offering a potential cure and eliminating the need for lifelong medication.
• The NHS trial, led by UCLH and UCL, uses genetically modified cells to target and attack problem cells, showing early indications of revolutionizing lupus treatment.
• Patients who underwent CAR T-cell therapy in Germany have achieved remission and discontinued lupus drugs, demonstrating the therapy's potential for long-term benefits.
• The CAR T-cell therapy, obecabtagene autoleucel (obe-cel), is being evaluated in a clinical trial sponsored by Autolus Limited, with hopes of replicating positive outcomes.
NHS Offers CAR T-cell Therapy to Lupus Patients in Groundbreaking Trial
• Three patients in the UK receive CAR T-cell therapy on the NHS in a trial offering potential remission for severe lupus, a disease affecting 70,000 in the UK.
• The therapy genetically modifies immune cells to target and attack cells driving lupus inflammation, providing a possible cure where only immunosuppression was available.
• Katie Tinkler, a lupus patient for 30 years, expresses hope that the trial's results will offer an endpoint for those with autoimmune diseases, improving their quality of life.
• University College London Hospitals NHS Foundation Trust (UCLH) is conducting the trial, marking a significant step forward in treating autoimmune conditions like lupus.
CAR T-Cell Therapy Shows Promise in Treating Severe Lupus in UK Trial
• Three patients in the UK have received CAR T-cell therapy for severe lupus, a potentially life-threatening autoimmune condition, in a new NHS trial led by UCLH and UCL.
• Early results from a German study indicate that CAR T-cell therapy could induce drug-free remission in lupus patients, offering a possible cure and revolutionizing treatment.
• The CAR T-cell therapy involves genetically modifying a patient's own immune cells to target and eliminate the cells causing lupus, potentially correcting the underlying defect of the disease.
• The clinical trial, sponsored by Autolus Limited, will follow patients for 15 years to fully assess the long-term effects of obecabtagene autoleucel (obe-cel) in treating lupus.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath